New Retina Radio By Eyetube

How did patients with PDR fare after being lost to follow-up for at least 1 year and then returning to the clinic? Kyle Kovacs, MD, is joined by Matt Starr, MD, and Nita Valikodath, MD, MS, to explore a recent paper that leveraged the power the IRIS Registry to assess real-world outcomes for this important subset of patients. 

Podcast co-hosts David Fell, MD, and Justin Muste, MD, are joined by Joshua H. Uhr, MD, and Arnulfo Garza-Reyes, MD, to share their experiences with scleral buckling. They discuss the utility of buckling for various cases, encircling bands versus elements, and tips for surgical success. 

Are you ready to accelerate your understanding of retina care?Join Dr. Nemo Patel as he speaks with Dr. Patrick Staropoli, a fellow retina specialist and professional race car driver, in an engaging discussion about Geographic Atrophy (GA) secondary to AMD.In this episode, Dr. Staropoli shares how the principles of racing—split-second decision-making, teamwork, and maintaining focus under pressure—influence his approach to treating GA. Together, they'll explore the evolving GA treatment landscape and emphasize the critical role of early detection and timely referral. Please see full Prescribing Information at http://bit.ly/4jXHTsb. This episode is sponsored by Apellis Pharmaceuticals, which developed its content and compensated the speakers.

Join Dr. Nemo Patel, Dr. Matthew Donovan, and Dr. Danny Mammo as they share real-world insights on how the next generation of retina specialists are optimizing their patient care by adopting FDA-approved therapies for appropriate patients. Together, they explore how to navigate patient selection, safety monitoring, and workflow integration—while maintaining efficiency and patient confidence. The conversation highlights how practices are evolving to meet the growing need for GA management, from staff training and patient education to effective collaboration with referring optometrists.Listen in to gain actionable strategies that you can implement in your practice today. Please see full Prescribing Information at http://bit.ly/4jXHTsb. This episode is sponsored by Apellis Pharmaceuticals, which developed its content and compensated the speakers.

Dr. Nemo Patel is joined by Drs. Sam Minaker and Has Al-khersan, who share lessons learned early in their careers about connecting with patients, setting expectations, and integrating therapy for geographic atrophy (GA) secondary to AMD into their respective practices. Together they address how to discuss complex diseases with patients, involve family members in treatment discussions, and build rapport through empathy and transparency. The conversation also highlights practical approaches for team training, workflow efficiency, and addressing real-world challenges in GA care. Please see full Prescribing Information at http://bit.ly/4jXHTsb. This episode is sponsored by Apellis Pharmaceuticals, which developed its content and compensated the speakers.

What types of delays do Stargardt disease patients experience when it comes to diagnosis? And what are the implications for such delays? Alexis Warren, MD, is joined by Jesse Sengillo, MD, and Sruthi Arepalli, MD, to discuss findings from a recent paper quantifying delays in diagnosis and suggesting means by which such delays could be mitigated.

Podcast co-hosts David Fell, MD, and Justin Muste, MD, sit down with Wills Eye fellow Flavius Beca, MD, to discuss the highs and lows of fellowship training, including successful cases of uveitis, clinical pearls for pneumatic retinopexy, and the challenges of treating retinal tears and detachments with vitrectomy and scleral buckling.

How do we know when a retina fellow is truly ready for independent surgery? Nikisha Kothari, MD, moderates a discussion with Jesse Sengillo, MD, and Nicholas Farber, MD, about a new survey study comparing perspectives from fellowship program directors and recent graduates on surgical volumes, teaching tools, autonomy, and competency benchmarks. The group explores areas of agreement, gaps in current training, and the push for more systematic assessment models in retina training.

How should retina specialists integrate next-generation anti-VEGFs into everyday wet AMD care? In this episode of “Anti-VEGFs: The Next Generation,” David Miller, MD, speaks with Esther Kim, MD, and Ehsan Rahimy, MD, about real-world issues facing wet AMD care, such as navigating crowded drug fridges, attempting interval extensions, and switching from legacy agents to next-generations treatments.  This editorially independent series is supported with advertising by Regeneron.

How should retina specialists integrate next-generation anti-VEGF agents into real-world DME care? In this episode of “Anti-VEGFs: The Next Generation,” David Miller, MD, speaks with Esther Kim, MD, and Ehsan Rahimy, MD, about first-line agent selection, when to transition to newer options, how to incorporate steroids thoughtfully, and crafting dosing strategies that balance durability, efficacy, and adherence for working-age patients—without overpromising outcomes.This editorially independent series is supported with advertising by Regeneron.

Can smarter strategies to tame retinal fluid fluctuations actually improve long-term vision? In episode 3 of this miniseries, host Jay Sridhar, MD, and panelists Durga Borkar, MD, MMCi, and Christina Weng, MD, MBA, examine the data linking sustained delivery of therapy, reductions in retinal thickness changes, and positive long-term vision outcomes. After the break, the trio looks ahead to sustained TKI therapy via EYP-1901 (Duravyu, EyePoint Pharmaceuticals) by examining data from the DAVIO-2 study. Drs. Sridhar, Borkar, and Weng are paid consultants of EyePoint Pharmaceuticals; however, the statements made are the opinions of Drs. Sridhar, Borkar, and Weng for educational purposes only; their statements are not intended as medical advice or the opinion of EyePoint.

Do retinal fluid fluctuations quietly erode long-term vision? In episode 2 of a 3-part roundtable series, moderator Jay Sridhar, MD joins guests Maggie Runner, MD, and Veeral Sheth, MD, MBA, to translate key data into clinic-ready tactics. They unpack how volatility—not just volume—of fluid correlates with outcomes, which fluid compartments matter most, and why durability reduces “yo-yo” anatomy. Drs. Sridhar, Runner, and Sheth are paid consultants of EyePoint Pharmaceuticals; however, the statements made are the opinions of Drs. Sridhar, Runner, and Sheth for educational purposes only; their statements are not intended as medical advice or the opinion of EyePoint.

In this first episode of a 3-part roundtable series, moderator Jay Sridhar, MD, speaks with David Sarraf, MD, and Danny Mammo, MD, about retinal fluid fluctuation as a modifiable driver of outcomes in neovascular AMD and DME. The panel defines fluctuation across compartments, examines practical barriers to longitudinal OCT tracking, and assesses the undertreatment gap in real-world practice.  Drs. Sridhar, Mammo, and Sarraf are paid consultants of EyePoint Pharmaceuticals; however, the statements made are the opinions of Drs. Sridhar, Mammo, and Sarraf for educational purposes only; their statements are not intended as medical advice or the opinion of EyePoint.

How are the world's leading mind on GA management educating patients about GA so they follow-up with their providers? Host Anat Loewenstein, MD, convenes a roundtable with Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD, to review their specific approaches to GA management, patient conversations, and education for patients and caregivers. Plus, are AREDS supplements an option for GA patients? 

At what point in their disease do world-renowned retina specialists want to see patients with GA? Host Anat Loewenstein, MD, leads a candid roundtable with Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD, on modern referral patterns, monitoring intervals, and fellow-eye surveillance. The panel explores the utility of OCT and FAF imaging, discusses patient/caregiver education, and the promise of AI tools in caring for GA patients. 

Does antibiotic prophylaxis prior to intravitreal injection affect the risk of endophthalmitis? Join New Retina Radio Journal Club with VBS moderator Alexis Warren, MD, as she and panelists Sruthi Arepalli, MD, and Jesse Sengillo, MD, sort out the details of a recent paper and discuss whether these findings alter clinical practice. 

How do you decide when GA patients are ready for complement inhibition—and how do you keep them on therapy in the real world? In episode 3 of The Nuts and Bolts of GA Therapy, moderator Charles Wykoff, MD, PhD, speaks with Kenneth Fan, MD, MBA, and Sruthi Arepalli, MD, about early vs conservative initiation, nuanced counseling on expectations and safety, and how imaging informs treatment decisions. Editorially independent content, supported by an educational grant from Apellis Pharmaceuticals.

What do GLP-1 receptor agonists mean for the future of retinal disease? Aleksandra Rachitskaya, MD, joins us to review the ever-evolving data on the relationship between retinal disease and GLP-1 RA use. Could these drugs protect against the development of retinal disease? And Julia Haller, MD, explains her vision of what the future of retina looks like. Who needs to be included in the crafting of best practices to ensure that retina specialists offer the highest quality care? Join us on this episode to find out. 

Could a biologic that addresses uveitic macular edema (UME) change the treatment landscape for uveitis patients? Rahul Khurana, MD, joins us to review data from the MEERKAT and SANDCAT trials assessing vamikibart (Genentech/Roche) for UME.  And Arshad Khanani, MD, MA, joins us to review the open-label extension study of GATHER2. What effect does avacincaptad pegol (Izervay, Astellas) have 2 years after the initial study was completed? Join us to hear details about these late-breaking presentations from AAO 2025. 

The dry AMD pipeline is packed. Join New Retina Radio as we break it down with Peter Kaiser, MD, whose podium presentation at AAO 2025 offered a survey of developmental projects in dry AMD. What should we look forward to? And Michel Michaelides, MD, shares details from the DRAGON study, which examined the safety and efficacy of tinlarebant (Belite Bio) for the treatment of Stargardt disease. Could a once-daily oral tablet lead to positive outcomes for patients? Listen to the episode to learn more.